Lessons from type I interferons in ulcerative colitis

Gut

Volumn 60, Issue 4, 2011, Pages 430-431

  Kaser, Arthur ^a,b   Blumberg, Richard S ^c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; CD1D ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 6; PLACEBO; RECOMBINANT INTERFERON; T LYMPHOCYTE RECEPTOR;

ANTIGEN EXPRESSION; CYTOKINE RELEASE; DOWN REGULATION; DRUG EFFICACY; ENVIRONMENTAL FACTOR; HUMAN; INTESTINE EPITHELIUM; NATURAL KILLER CELL; NONHUMAN; NOTE; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REMISSION; ULCERATIVE COLITIS; UPREGULATION;

COLITIS, ULCERATIVE; HUMANS; INTERFERON TYPE I; INTERFERON-BETA; INTERLEUKIN-13;

EID: 79952535214     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2010.229138     Document Type: Note

References (15)

1. Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol 2010;28:573-621.
2. Heller F, Fuss IJ, Nieuwenhuis EE, et al. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity 2002;17:629-38. (Pubitemid 35351508)
3. Fuss IJ, Heller F, Boirivant M, et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest 2004;113:1490-7. (Pubitemid 39071705)
4. Middendorp S, Nieuwenhuis EE. NKT cells in mucosal immunity. Mucosal Immunol 2009;2:393-402.
5. Bleicher PA, Balk SP, Hagen SJ, et al. Expression of murine CD1 on gastrointestinal epithelium. Science 1990;250:679-82. (Pubitemid 120034289)
6. Blumberg RS, Terhorst C, Bleicher P, et al. Expression of a nonpolymorphic MHC class I-like molecule, CD1D, by human intestinal epithelial cells. J Immunol 1991;147:2518-24.
7. van de Wal Y, Corazza N, Allez M, et al. Delineation of a CD1d-restricted antigen presentation pathway associated with human and mouse intestinal epithelial cells. Gastroenterology 2003;124:1420-31. (Pubitemid 36531815)
8. Kaser A, Molnar C, Tilg H. Differential regulation of interleukin 4 and interleukin 13 production by interferon alpha. Cytokine 1998;10:75-81. (Pubitemid 28077705)
9. McRae BL, Picker LJ, van Seventer GA. Human recombinant interferon-beta influences T helper subset differentiation by regulating cytokine secretion pattern and expression of homing receptors. Eur J Immunol 1997;27:2650-6. (Pubitemid 27453856)
10. Sumer N, Palabiyikoglu M. Induction of remission by interferon-alpha in patients with chronic active ulcerative colitis. Eur J Gastroenterol Hepatol 1995;7:597-602.
11. Tilg H, Vogelsang H, Ludwiczek O, et al. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut 2003;52:1728-33. (Pubitemid 37510393)
12. Nikolaus S, Rutgeerts P, Fedorak R, et al. Interferon beta-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut 2003;52:1286-90. (Pubitemid 37026460)
13. Musch E, Andus T, Kruis W, et al. Interferon-beta-1a for the treatment of steroid-refractory ulcerative colitis: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2005;3:581-6. (Pubitemid 40824751)
14. Pena-Rossi C, Schreiber S, Golubovic G, et al. Clinical trial: a multicentre, randomized, double-blind, placebo-controlled, dose-finding, phase II study of subcutaneous interferon-beta-la in moderately active ulcerative colitis. Aliment Pharmacol Ther 2008;28:758-67.
15. Mannon PJ, Hornung RL, Yang Z, et al. Suppression of inflammation in ulcerative colitis by interferon-β-1a is accompanied by inhibition of IL-13 production. Gut 2011;60:449-55.